Trevi Therapeutics appoints David Hastings as chief financial officer

Go back to Trevi Therapeutics appoints David Hastings as chief financial officer
(NASDAQ: TRVI) Delayed: 17.05 --0 (-0%)
Previous Close $17.05    52 Week High
Open $17.05    52 Week Low
Day High $17.05    P/E N/A 
Day Low $17.05    EPS
Volume 2,655